Tilray (NASDAQ:TLRY) Announces Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Tilray (NASDAQ:TLRY) posted its quarterly earnings results on Friday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07), Zacks reports. Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The business had revenue of $210.90 million for the quarter, compared to analysts’ expectations of $216.34 million. Tilray’s revenue was up 8.7% on a year-over-year basis. Tilray updated its FY 2025 guidance to EPS.

Tilray Stock Performance

TLRY stock traded down $0.13 during trading on Friday, hitting $1.25. 27,340,392 shares of the company traded hands, compared to its average volume of 45,380,848. The company has a market cap of $1.12 billion, a PE ratio of -4.61 and a beta of 2.08. Tilray has a 1 year low of $1.14 and a 1 year high of $2.97. The stock’s 50-day simple moving average is $1.37 and its 200 day simple moving average is $1.62. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.47 and a quick ratio of 1.57.

Insider Activity

In other Tilray news, CFO Carl A. Merton acquired 26,000 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was acquired at an average cost of $1.36 per share, for a total transaction of $35,360.00. Following the completion of the transaction, the chief financial officer now directly owns 26,000 shares of the company’s stock, valued at $35,360. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.87% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Roth Mkm cut their price objective on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research note on Friday, October 11th.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.